Briarcliff Manor, NY, United States of America

Su Liang

USPTO Granted Patents = 1 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Su Liang

Introduction

Su Liang is an accomplished inventor based in Briarcliff Manor, NY. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic use. His innovative work focuses on improving the stability and efficacy of treatments for autoimmune diseases.

Latest Patents

Su Liang holds a patent for an "Anti-FcRn antibody or antigen binding fragment thereof with improved stability." This patent describes an anti-FcRn antibody that binds non-competitively with IgG, offering enhanced stability compared to the parent antibody, HL161AN. The invention aims to reduce the production rate of aggregates while maintaining biological activity, which is crucial for effectively lowering pathogenic autoantibodies in the blood. This advancement has the potential to improve treatment options for autoimmune diseases.

Career Highlights

Throughout his career, Su Liang has worked with notable companies in the biotechnology sector. He has been associated with Hanall Biopharma Co., Ltd. and Immunovant Sciences GmbH, where he has contributed to various research and development projects. His expertise in antibody engineering has positioned him as a valuable asset in the industry.

Collaborations

Su Liang has collaborated with several professionals in his field, including William Louis Macias and Hyeakyung Ahn. These collaborations have fostered innovation and have been instrumental in advancing research in antibody therapies.

Conclusion

Su Liang's contributions to the field of biotechnology, particularly through his patent on anti-FcRn antibodies, highlight his role as a leading inventor. His work not only enhances the stability of therapeutic antibodies but also paves the way for more effective treatments for autoimmune diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…